Boehringer Ingelheim acquires ViraTherapeutics for $245 mln
Boehringer Ingelheim has acquired Austria-based ViraTherapeutics, a developer of virus-based immunotherapeutics for the treatment of cancer, for $245 million. ViraTherapeutics was a portfolio company of EMBL Ventures.
13 September 2018•4 mins read
